Safety Study of GMDTC Injection in Participants With Excessive Cadmium

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 8, 2024

Primary Completion Date

October 21, 2024

Study Completion Date

December 5, 2024

Conditions
Cadmium Exceeds the Standard
Interventions
DRUG

GMDTC for injection

GMDTC for injection with a specification of 0.5g/vial, 500mg,1000mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.

OTHER

Normal saline

0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial

Trial Locations (1)

410000

Hunan Occupational Disease Prevention and Control Institute, Changsha

All Listed Sponsors
lead

Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT06199349 - Safety Study of GMDTC Injection in Participants With Excessive Cadmium | Biotech Hunter | Biotech Hunter